These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 16627301)

  • 41. Comparison of costs and utilization among buprenorphine and methadone patients.
    Barnett PG
    Addiction; 2009 Jun; 104(6):982-92. PubMed ID: 19466922
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Feasibility of buprenorphine maintenance therapy programs in the Ukraine: first promising treatment outcomes.
    Schaub M; Subata E; Chtenguelov V; Weiler G; Uchtenhagen A
    Eur Addict Res; 2009; 15(3):157-62. PubMed ID: 19420948
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Using buprenorphine to facilitate entry into residential therapeutic community rehabilitation.
    Collins ED; Horton T; Reinke K; Amass L; Nunes EV
    J Subst Abuse Treat; 2007 Mar; 32(2):167-75. PubMed ID: 17306725
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multi-centre observational study of buprenorphine use in 32 Italian drug addiction centres.
    Leonardi C; Hanna N; Laurenzi P; Fagetti R;
    Drug Alcohol Depend; 2008 Apr; 94(1-3):125-32. PubMed ID: 18162330
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Exposure to opioid maintenance treatment reduces long-term mortality.
    Gibson A; Degenhardt L; Mattick RP; Ali R; White J; O'Brien S
    Addiction; 2008 Mar; 103(3):462-8. PubMed ID: 18190664
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomized trial of effectiveness and cost-effectiveness of observed versus unobserved administration of buprenorphine-naloxone for heroin dependence.
    Bell J; Shanahan M; Mutch C; Rea F; Ryan A; Batey R; Dunlop A; Winstock A
    Addiction; 2007 Dec; 102(12):1899-907. PubMed ID: 17784896
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of a transdermal buprenorphine formulation in opioid detoxification.
    Lanier RK; Umbricht A; Harrison JA; Nuwayser ES; Bigelow GE
    Addiction; 2007 Oct; 102(10):1648-56. PubMed ID: 17854341
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A chart review based comparative study of retention rates for two dispensing regimens for buprenorphine for subjects with opioid dependence at a tertiary care substance use disorder treatment center.
    Balhara YP
    J Opioid Manag; 2014; 10(3):200-6. PubMed ID: 24944070
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of the use of buprenorphine for opioid withdrawal in an emergency department.
    Berg ML; Idrees U; Ding R; Nesbit SA; Liang HK; McCarthy ML
    Drug Alcohol Depend; 2007 Jan; 86(2-3):239-44. PubMed ID: 16930865
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Using buprenorphine short-term taper to facilitate early treatment engagement.
    Brigham GS; Amass L; Winhusen T; Harrer JM; Pelt A
    J Subst Abuse Treat; 2007 Jun; 32(4):349-56. PubMed ID: 17481458
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Substitution therapy with buprenorphine to pregnant women with opioid dependency].
    Olofsson MJ; Ege PP
    Ugeskr Laeger; 2003 Sep; 165(38):3605. PubMed ID: 14556389
    [No Abstract]   [Full Text] [Related]  

  • 52. Behavioral drug and HIV risk reduction counseling (BDRC) with abstinence-contingent take-home buprenorphine: a pilot randomized clinical trial.
    Chawarski MC; Mazlan M; Schottenfeld RS
    Drug Alcohol Depend; 2008 Apr; 94(1-3):281-4. PubMed ID: 18164145
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A comparison between low-magnitude voucher and buprenorphine medication contingencies in promoting abstinence from opioids and cocaine.
    Gross A; Marsch LA; Badger GJ; Bickel WK
    Exp Clin Psychopharmacol; 2006 May; 14(2):148-56. PubMed ID: 16756418
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Brief vs. extended buprenorphine detoxification in a community treatment program: engagement and short-term outcomes.
    Katz EC; Schwartz RP; King S; Highfield DA; O'Grady KE; Billings T; Gandhi D; Weintraub E; Glovinsky D; Barksdale W; Brown BS
    Am J Drug Alcohol Abuse; 2009; 35(2):63-7. PubMed ID: 19199166
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Buprenorphine with bupivacaine for intraoral nerve blocks to provide postoperative analgesia in outpatients after minor oral surgery.
    Modi M; Rastogi S; Kumar A
    J Oral Maxillofac Surg; 2009 Dec; 67(12):2571-6. PubMed ID: 19925973
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Using buprenorphine for outpatient opioid detoxification.
    Manlandro JJ
    J Am Osteopath Assoc; 2007 Sep; 107(9 Suppl 5):ES11-6. PubMed ID: 17908825
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users.
    Alho H; Sinclair D; Vuori E; Holopainen A
    Drug Alcohol Depend; 2007 Apr; 88(1):75-8. PubMed ID: 17055191
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Crushing buprenorphine tablets.
    Muhleisen P; Spence J; Nielsen S
    Drug Alcohol Rev; 2003 Dec; 22(4):471-2. PubMed ID: 14660137
    [No Abstract]   [Full Text] [Related]  

  • 59. Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment.
    Nielsen S; Dietze P; Lee N; Dunlop A; Taylor D
    Addiction; 2007 Apr; 102(4):616-22. PubMed ID: 17286641
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Potential of buprenorphine/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders.
    McCann DJ
    Clin Pharmacol Ther; 2008 Apr; 83(4):627-30. PubMed ID: 18212797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.